PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 260 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q1 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $601,000 | -42.4% | 72,097 | -8.0% | 0.00% | -50.0% |
| Q2 2023 | $1,043,000 | +0.1% | 78,341 | -12.9% | 0.00% | 0.0% |
| Q1 2023 | $1,042,000 | +47.2% | 89,906 | +3.7% | 0.00% | 0.0% |
| Q4 2022 | $708,000 | +12.4% | 86,723 | -19.8% | 0.00% | 0.0% |
| Q3 2022 | $630,000 | -10.4% | 108,138 | -32.6% | 0.00% | 0.0% |
| Q2 2022 | $703,000 | -63.0% | 160,423 | -23.1% | 0.00% | -50.0% |
| Q1 2022 | $1,902,000 | +2.1% | 208,665 | +129.6% | 0.00% | 0.0% |
| Q4 2021 | $1,862,000 | -10.3% | 90,885 | +11.9% | 0.00% | -33.3% |
| Q3 2021 | $2,076,000 | -28.0% | 81,239 | -1.6% | 0.01% | -25.0% |
| Q2 2021 | $2,885,000 | -7.5% | 82,560 | -11.1% | 0.01% | -20.0% |
| Q1 2021 | $3,119,000 | +740.7% | 92,833 | +549.2% | 0.01% | +400.0% |
| Q4 2020 | $371,000 | +267.3% | 14,300 | -48.5% | 0.00% | +100.0% |
| Q2 2017 | $101,000 | +7.4% | 27,785 | +35.1% | 0.00% | 0.0% |
| Q1 2017 | $94,000 | – | 20,560 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |